A Randomized, Controlled Trial of Cannabis in Healthy Volunteers Evaluating Simulated Driving, Field Performance Tests and Cannabinoid Levels

INVESTIGATORS: Thomas Marcotte, Ph.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: A Randomized, Controlled Trial of Cannabis in Healthy Volunteers Evaluating Simulated Driving, Field Performance Tests and Cannabinoid Levels

FUNDING SOURCE: State of California

PROJECT TYPE: Clinical Study

STATUS: ACTIVE

ABSTRACT:

This study was authorized by the California Legislature (Assembly Bill 266, the Medical Marijuana Regulation and Safety Act) to help with detection of driving under the influence of cannabis. Healthy volunteers will inhale smoked cannabis with either 0% (placebo), 6.7%, or 12.6% Δ9-THC at the beginning of the day, and then complete driving simulations, iPad-based performance assessments, and bodily fluid draws (e.g., blood, saliva, breath) before the cannabis smoking and hourly over the subsequent 7 hours after cannabis smoking. The purpose is to determine (1) the relationship of the dose of Δ9-THC on driving performance and (2) the duration of driving impairment in terms of hours from initial use, (3) if saliva or expired air can serve as a useful substitute for blood sampling of Δ9-THC in judicial hearings and (4) if testing using an iPad can serve as a useful adjunct to the standardized field sobriety test in identifying acute impairment from cannabis.

 

Interested in participating? Click here to contact us.

The CBD Expert Series: Q&A with a National Leader in Cannabis Research

Nick Musica, CBD Oil Review, August 21, 2019

Recently, Nick Musica of CBD Oil Review had the privilege of speaking with one of the most influential figures in cannabis research, Dr. Igor Grant. Dr. Grant is the Director of the Center for Medicinal Cannabis Research (CMCR) at the University of California, San Diego, as well as a Distinguished Professor in the Department of Psychiatry.

Current CMCR studies are examining the effects of cannabis, and cannabidiol (CBD) specifically, on conditions like autism, psychosis, bipolar disorder, and pain, to name a few.

There is, quite possibly, no one who understands the benefits and effects of CBD better than Dr. Grant. Meet the researcher behind the research.

Read the article here


Pure CBD Won't Make You Fail a Drug Test, But…

Amy Norton, HealthDay, August 9, 2019

As the CBD craze sweeps the nation, some users may wonder whether the cannabis extract can make them fail a drug test. A preliminary study suggests the answer is "no" -- at least if the CBD is pure.

Researchers found that CBD, or cannabidiol, did not react with either of two commercially available tests used to screen for marijuana use. However, another cannabis compound -- cannabinol (CBN) -- did.

CBD and CBN are two of many chemicals found in cannabis plants. They differ from THC, the source of the marijuana "high." CBD is present in marijuana but more abundant in hemp -- cannabis plants that have little THC. CBN, meanwhile, is a THC derivative.

If you think CBD products are suddenly everywhere, you're right: There has been an explosion since last year, when Congress lifted a decades-old ban on growing hemp.

Read the article here


Weed Is Everywhere, So Why Is It Still A Medical Mystery?

Seeker, June 23, 2019


Regulators hungry for evidence as FDA weighs allowing CBD in food, dietary supplements

Angelica LaVito, CNBC, May 31, 2019

Food and Drug Administration regulators grilled manufacturers and advocates Friday for evidence that CBD actually does anything they claim it does.

Companies are adding CBD, short for cannabidiol, to just about everything, including makeup, tea, pet treats and soft drinks — even though there's little data to support the many claims of its benefits. FDA regulators trying to learn more about the cannabis compound held the agency's first hearing on it Friday.

More than 100 people testified at the hearing. Speakers pushed the FDA to set up a regulatory framework to legally add CBD to food products and dietary supplements. They praised CBD and the purported benefits — and FDA panelists repeatedly asked for data. Scientists warned of the little research and many potential risks CBD brings.

Read the story here


Three years into legal cannabis and California still doesn’t have a reliable test for driving while high

Brooke Staggs, Orange County Register, May 31, 2019

Nearly three years after California voters approved a cannabis legalization bill that promised, among other things, to clarify the issue of driving while high, researchers and law enforcement have few concrete answers about a potentially deadly problem.

It’s unclear, for example, if marijuana-related arrests or car crashes have increased statewide. It’s up to each county to track that data, and many still don’t distinguish between cannabis and other drugs in their arrest and accident reports.

There also aren’t yet any reliable methods for testing whether drivers were actually impaired by marijuana when they’re behind the wheel. Research in this area is hampered by federal law and left scrambling to catch up with the wave of marijuana legalization that continues to sweep the country.

Read the rest of the article here


Igor Grant, MD

Marijuana as Medicine: Can We See Past the Smoke?
North American Cannabis Summit presentation January 2019 (PDF)


Igor Grant, MD

Introduction/Overview
CMCR Symposium, June 2018


Daniele Piomelli, MD, PhD, PharmD

The health impact of cannabis
CMCR Symposium, June 2018


Ziva Cooper, PhD

Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018


Iain McGregor, PhD

Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018


Copyright © 2019 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego
cmcr@ucsd.edu | HNRP |